Sounds like you have a beef with RAC.
I was a shareholder in RAC during 2020 with various entry prices from 25c to 50c.
Bisantrene has a lot of clinical data (20+ years) of trials where it was shown to be safe and with little to no side effects. This data is valuable and still applicable in the trials they are doing today.
Bisantrene does not offer a singular pipeline of treatments and opportunities for success. In fact, many pipelines.
I suggest you take some time to review their website, presentations and read some of wombat777 posts.
RAC has multi $Bn potential.
I am no longer a shareholder of RAC.
But I have accumulated a holding in IMU from around 10-12c. I prefer IMU though as I think the Board of Directors, Senior Managers, Research team and Advisors are outstanding.
I think both companies have a chance of being very successful and hopefully help many unfortunate people suffering from different forms of Cancer.
Friday thoughts IMU, page-162
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.8¢ |
Change
-0.001(1.04%) |
Mkt cap ! $353.3M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 4.8¢ | 4.7¢ | $346.1K | 7.244M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 32 | 4323849 | 4.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.8¢ | 1810811 | 15 |
View Market Depth
| Last trade - 15.42pm 12/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |